At 21:00 p.m. yesterday, the lancet, an international academic journal, published the results of phase I clinical trials of the world’s first new crown vaccine with recombinant adenovirus-5 vector: the vaccine is safe and has successfully produced antibodies in volunteers. The research results come from the team of Chen Wei, academician of Chinese Academy of engineering.
They showed immunogenicity and tolerance 28 days after the new crown was administered to volunteers, the paper said.
In healthy adults, the humoral immune response to sars-cov-2 peaked on the 28th day after vaccination, and the rapid specific T cell response was recorded on the 14th day after vaccination.
However, Chen Wei also pointed out that although the test results show that the new coronavirus vaccine has a good development prospect, it is still necessary to verify the effectiveness of the vaccine, and it is too early to talk about the final listing.
+ There are no comments
Add yours